Pegvisomant: Current and potential novel therapeutic applications

Expert Opinion on Biological Therapy

Volumn 9, Issue 12, 2009, Pages 1553-1563

  Thankamony, Gn Ajay ^a   Dunger, David B ^a   Acerini, Carlo L ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Acromegaly; Diabetic nephropathy; Diabetic retinopathy; GH antagonist; Growth hormone receptor antagonist; Growth hormone secretory reserve

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; OCTREOTIDE; PEGVISOMANT; PLACEBO; SOMATOSTATIN;

ACROMEGALY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; EMBASE; HUMAN; HYPOPHYSIS ADENOMA; INSULIN DEPENDENT DIABETES MELLITUS; LOADING DRUG DOSE; MEDLINE; MONOTHERAPY; REVIEW; SINGLE DRUG DOSE;

ACROMEGALY; ANIMALS; ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; HYPOGLYCEMIC AGENTS; PITUITARY DISEASES; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 70450179728     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903449222     Document Type: Review

References (92)

1. Johannsson G. Treatment of growth hormone deficiency in adults. Horm Res 2009;71(Suppl 1):116-122
2. Frago LM, Chowen JA. Basic physiology of the growth hormone/insulin-like growth factor axis. Adv Exp Med Biol 2005;567:1-25
3. Fan Y, Menon RK, Cohen P, et al. Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism. J Biol Chem 2009;284(30):19937-19944
4. Ultsch MH, Somers W, Kossiakoff AA, de Vos AM. The crystal structure of affinity-matured human growth hormone at 2 A ° ́ resolution. J Mol Biol 1994;236(1):286-299
5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: Discovery, development, and use in patients with acromegaly. Endocr Rev 2002;23(5):623-646
6. de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: Crystal structure of the complex. Science 1992;255(5042):306-312
7. Brown RJ, Adams JJ, Pelekanos RA, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005;12(9):814-821
8. Birzniece V, Sata A, Ho KK. Growth hormone receptor modulators. Rev Endocr Metab Disord 2009;10(2):145-156
9. Dominici FP, Argentino DP, Munoz MC, et al. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm IGF Res 2005;15(5):324-336
10. Higham CE, Trainer PJ. Growth hormone excess and the development of growth hormone receptor antagonists. Exp Physiol 2008;93(11):1157-1169
11. Rose DR, Clemmons DR. Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 2002;12(6):418-424
12. Harris JM, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40(7):539-551
13. EMEA. Eurpoean Public Assessment Reports for authorised medicinal products for human use; Somavert (Scientfic Discussion). European Medicines Agency, 2004. Available from: http://www.emea. europa.eu/humandocs/Humans/EPAR/ somavert/somavert.htm [Last accessed 30 November 2009]
14. Veldhuis JD, Bidlingmaier M, Anderson SM, et al. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J Clin Endocrinol Metab 2002;87(12):5737-5745
15. Berg CA, Pokrajac A, Bidlingmaier M, et al. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD). Clin Endocrinol (Oxf) 2009;70(3):439-445
16. Yin D, Vreeland F, Schaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007;13(3):1000-1009
17. Brian SR, Bidlingmaier M, Wajnrajch MP, et al. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 2007;92(9):3374-3377
18. Bex M, Abs R, T'Sjoen G, et al. AcroBel- the Belgian registry on acromegaly: A survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 2007;157(4):399-409 (Pubitemid 350018442)
19. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004;151(4):439-446
20. Biermasz NR, van Dulken H, Roelfsema F. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J Clin Endocrinol Metab 2000;85(12):4596-4602 (Pubitemid 32157639)
21. Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotideLAR: A long-term(up tonine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006;91(4):1397-1403
22. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. Therapeutic options in the management of acromegaly: Focus on lanreotide autogel. Biologics 2008;2(3):463-479
23. Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007;66(6):859-868
24. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94(5):1509-1517
25. Jenkins PJ, Bates P, Carson MN, et al. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J Clin Endocrinol Metab 2006;91(4):1239-1245
26. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-1177
27. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German pegvisomant observational study. Eur J Endocrinol 2007;156(1):75-82
28. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358(9295):1754-1759
29. Higham CE, Chung TT, Lawrance J, et al. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 2009;71(1):86-91
30. Buchfelder M, Schlaffer S, Droste M, et al. The German ACROSTUDY: Past and present. Eur J Endocrinol 2009;161:S3. Published online 14 August 2009, doi: 10.1530/EJE-09-0350
31. Marazuela M, Lucas T, Alvarez-Escola C, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 2009;160(4):535-542
32. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 2005 90(10):5627-5631
33. Jawiarczyk A, Kaluzny M, Bolanowski M, et al. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly. Neuro Endocrinol Lett 2008;29(4):571-576
34. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005;365(9471):1644-1646
35. Trainer PJ, Ezzat S, D'Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 2009;71(4):549-557
36. Neggers SJ, van Aken MO, de Herder WW, et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93(10):3853-3859 .. The study suggests additional advantages for use of pegvisomant in acromegaly other than control of IGF-I levels.
37. Pivonello R, Galderisi M, Auriemma RS, et al. Treatment with growth hormone receptor antagonist in acromegaly: Effect on cardiac structure and performance. J Clin Endocrinol Metab 2007;92(2):476-482
38. Higham CE, Rowles S, Russell-Jones D, et al. Pegvisomant improves insulin sensitivity and reduces overnight FFA concentrations in patients with acromegaly. J Clin Endocrinol Metab 2009;94(7):2459-2463
39. Lindberg-Larsen R, Moller N, Schmitz O, et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 2007;92(5):1724-1728
40. Barkan AL, Burman P, Clemmons DR, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005;90(10):5684-5691
41. Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007;92(1):190-195
42. Bianchi A, Mazziotti G, Tilaro L, et al. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. Pituitary 2008;12(3):196-199
43. Goldenberg N, Racine MS, Thomas P, et al. Treatment of pituitary gigantism with the growth hormone receptor antagonist pegvisomant. J Clin Endocrinol Metab 2008;93(8):2953-2956
44. Ahmed ML, Ong KK, Watts AP, et al. Elevated leptin levels are associated with excess gains in fat mass in girls, but not boys, with type 1 diabetes: longitudinal study during adolescence. J Clin Endocrinol Metab 2001;86(3):1188-1193
45. Pal BR, Matthews DR, Edge JA, et al. The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia. Clin Endocrinol (Oxf) 1993;38(1):93-100
46. Acerini CL, Cheetham TD, Edge JA, Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 2000;43(1):61-68
47. Dunger DB. Diabetes in puberty. Arch Dis Child 1992;67(5):569-570
48. Orskov L, Moller N, Bak JF, et al. Effects of the somatostatin analog, octreotide, on glucose metabolism and insulin sensitivity in insulin-dependent diabetes mellitus. Metabolism 1996;45(2):211-217
49. Pietschmann P, Schernthaner G. The effect of pirenzepine on growth hormone and blood glucose levels in type I diabetes mellitus. A controlled study in patients on basal bolus insulin treatment. Acta Endocrinol (Copenh) 1988;117(3):315-319
50. Acerini CL, Patton CM, Savage MO, et al. Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350(9086):1199-1204
51. Moller N, Orskov H. Does IGF-I therapy in insulin-dependent diabetes mellitus limit complications? Lancet 1997;350(9086):1188-1189
52. Saukkonen T, Amin R, Williams RM, et al. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes. J Clin Endocrinol Metab 2004;89(9):4634-4641
53. Williams RM, Amin R, Shojaee-Moradie F, et al. The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with type 1 diabetes mellitus. Diabetologia 2003;46(9):1203-1210 .. This study demonstrated improvement in insulin sensitivity following pegvisomant administration in type 1 diabetes.
54. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000 43(10):1205-1223
55. Segev Y, Landau D, Marbach M, et al. Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I. J Am Soc Nephrol 1997;8(3):436-444
56. Miller SB, Rotwein P, Bortz JD, et al. Renal expression of IGF I in hypersomatotropic states. Am J Physiol 1990;259(2 Pt 2):F251-7
57. Doi T, Striker LJ, Quaife C, et al. Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1. Am J Pathol 1988;131(3):398-403
58. Hirschberg R, Rabb H, Bergamo R, Kopple JD. The delayed effect of growth hormone on renal function in humans. Kidney Int 1989;35(3):865-870 (Pubitemid 19082115)
59. Hoogenberg K, Sluiter WJ, Dullaart RP. Effect of growth hormone and insulin-like growth factor I on urinary albumin excretion: Studies in acromegaly and growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129(2):151-157
60. Dahlquist G, Stattin EL, Rudberg S. Urinary albumin excretion rate and glomerular filtration rate in the prediction of diabetic nephropathy; a long-term follow-up study of childhood onset type-1 diabetic patients. Nephrol Dial Transplant 2001;16(7):1382-1386
61. Janssen JA, Jacobs ML, Derkx FH, et al. Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82(9):2809-2815
62. Cummings EA, Sochett EB, Dekker MG, et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998;47(8):1341-1346
63. Manelli F, Bossoni S, Burattin A, et al. Exercise-induced microalbuminuria in patients with active acromegaly: Acute effects of slow-release lanreotide, a long-acting somatostatin analog. Metabolism 2000;49(5):634-639
64. Dullaart RP, Meijer S, Marbach P, Sluiter WJ. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients. Eur J Clin Invest 1992;22(7):494-502
65. Krempf M, Ranganathan S, Remy JP, et al. Effect of long-acting somatostatin analog (SMS 201-995) on high glomerular filtration rate in insulin dependent diabetic patients. Int J Clin Pharmacol Ther Toxicol 1990;28(7):309-311
66. Serri O, Beauregard H, Brazeau P, et al. Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991;265(7):888-892
67. Williams RM, Yuen K, White D, et al. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates. Clin Endocrinol (Oxf) 2006;65(4):439-445
68. Chen NY, Chen WY, Bellush L, et al. Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology 1995;136(2):660-667
69. Flyvbjerg A, Bennett WF, Rasch R, et al. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. Diabetes 1999;48(2):377-382
70. van Neck JW, Dits NF, Cingel V, et al. Dose-response effects of a new growth hormone receptor antagonist (B2036-PEG) on circulating, hepatic and renal expression of the growth hormone/ insulin-like growth factor system in adult mice. J Endocrinol 2000;167(2):295-303
71. Flyvbjerg A. Growth factors and diabetic complications. Diabet Med 1990;7(5):387-399
72. Merimee TJ. A follow-up study of vascular disease in growth-hormone- deficient dwarfs with diabetes. N Engl J Med 1978;298(22):1217-1222
73. Smith LE, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997;276(5319):1706-1709
74. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004;102(1):61-85
75. Beck R, Frank R, Kraker R. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108(12):2266-2272
76. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer 2001;85(3):428-430
77. Wang Z, Luque RM, Kineman RD, et al. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 2008;149(3):1366-1376
78. Shen Q, Lantvit DD, Lin Q, et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology 2007;148(10):4536-4544
79. Zhang X, Mehta RG, Lantvit DD, et al. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 2007;28(1):143-150
80. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002;13(5):653-668
81. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21(3):215-244
82. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001;94(3):487-492
83. Dagnaes-Hansen F, Duan H, Rasmussen LM, et al. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res 2004;24(6):3735-3742
84. Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: Effect of a specific receptor antagonist. J Neurosurg 1999;91(1):93-99
85. Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006;98(3):315-327
86. Ghigo E, Bellone J, Aimaretti G, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab 1996 81(9):3323-3327
87. Carel JC, Tresca JP, Letrait M, et al. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: A population register-based study. J Clin Endocrinol Metab 1997;82(7):2117-2121
88. Radetti G, Wu Z, Elsedfy HH, et al. Pegvisomant-primed GH stimulation test. Clin Endocrinol (Oxf) 2008;68(6):951-956
89. Brue T. ACROSTUDY: Status update on 469 patients. Horm Res 2009; 71(Suppl 1):34-38
90. Neggers SJ, de Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009;160(4):529-533
91. Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92(12):4598-4601
92. Buchfelder M, Weigel D, Droste M, et al. Pituitary tumor size in acromegaly during pegvisomant treatment: Experience from MR re-evaluations of the German pegvisomant observational study. Eur J Endocrinol 2009;71(1):27-35